Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3848 | Symptoms questionnare Wiki | 0.58 |
| drug2816 | Parents and Infants Engaged Wiki | 0.58 |
| drug4561 | lung ultrasound Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D065886 | Neurodevelopmental Disorders NIH | 0.41 |
| D000067877 | Autism Spectrum Disorder NIH | 0.31 |
| D001321 | Autistic Disorder NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000729 | Autistic behavior HPO | 0.31 |
| HP:0000717 | Autism HPO | 0.17 |
| HP:0000716 | Depressivity HPO | 0.11 |
Navigate: Correlations HPO
There are 3 clinical trials
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: the mean time patients devleoped IgM
Measure: Time to IgM Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgG Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgA Time: Evaluated within a 100 days followupDescription: Cohen's kappa coefficient calculated between the different serology kits used for evaluation
Measure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followupDescription: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 1-1.3 years from COVID-19 Infection
Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA)- long term Time: 1 yearDescription: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 1-1.3 years from COVID-19 Infection
Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) -long term Time: 1 yearThe objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
Covid-19 (English acronym meaning coronavirus disease 2019) is an emerging infectious disease caused by a strain of coronavirus called SARS-CoV-2. The current pandemic has resulted in a significant number of admissions in the emergency room (ER) due to suspicion of COVID-19 infection. Use of lung ultrasound is standard practice to diagnose acute respiratory failure in ER. Recently, typical lung ultrasonographic characteristics of COVID-19 disease has been described. During the COVID-19 pandemic, the use of this tool could be of interest in order to allow an early, simple and reliable triage in patients with suspected COVID-19 infection admitted in ER. In addition, the visualization of early signs in specific areas could be a predictive marker of the severity of the disease. The objective of this project will be to study the association between the signs on lung ultrasound and the result of RT-PCR in patients with suspected COVID-19 infection in the ER.
Description: Polymerase chain reaction tests after reverse transcription for the detection of covid-19 viral RNA will be done as biological test.
Measure: Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports